Biocompatible coating compositions

A coating composition and biocompatibility technology, applied in the field of biocompatible coating composition, can solve the problem that anticoagulant properties cannot be used for long-term support

Inactive Publication Date: 2015-09-09
UNIV OF MARYLAND BALTIMORE
View PDF0 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the anticoagulant properties of many of these coatings last only a short time and cannot be used for long-term support

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Biocompatible coating compositions
  • Biocompatible coating compositions
  • Biocompatible coating compositions

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0053] Preparation of primer solution:

[0054] According to a non-limiting exemplary embodiment, the surface to be coated may first be primed with the PVP solution. Specifically, a solution comprising 0.5-0.9% by weight of poly-N-vinyl-2-pyrrolidone (PVP) in alcohol was prepared separately for the application of the initial surface modification and this solution was referred to as the 'primer solution' .

[0055] Method of coating a surface or device:

[0056] Test fiber samples of hollow fiber membranes can be coated directly with a coating solution of Quat-heparin complex in an alcohol-rich solvent or primed with PVPV in alcohol prior to coating surfaces or devices , followed by a second coat using the coating solution mentioned above.

[0057] Accordingly, provided herein are methods comprising coating a surface with a primer solution comprising PVP followed by coating said surface with a QUAT solution comprising a quaternary ammonium salt and heparin.

[0058] The act...

Embodiment 1

[0074] The amount of immobilized heparin on the PVP heparin (PVP-HC) coated surface was compared to the heparin coated surface (HC) and the Corline heparin surface (CHS). Mix 200 μL of AT-III and 25 μL of heparin at a concentration of 0.5-15 μg / mL and incubate at 37° C. for 2 minutes. Then add 200 μL of FX a Mix into solution and incubate at 37°C for 1 minute. Next, add 200 μL of spectrozyme FX a Mix into solution and incubate at 37°C for 5 minutes. Add 200 µL of glacial acetic acid and mix thoroughly. Heparin absorption was then measured at 405 nm, thus quantifying the activity of heparin immobilized on the fiber surface. Figure 4 is a standard straight line depicting the activity of known amounts of heparin with respect to absorbance readings determined by spectrophotometric techniques. The amount of immobilized heparin from CHS, HC and PVP-HC coated fiber samples is indicated on the standard curve. Figure 4 It was demonstrated that PVP-HC has a higher amount of immo...

Embodiment 2

[0076] HFMs each coated with different exemplary coatings of the present invention were tested to determine their biocompatibility and ability to hinder protein absorption, platelet adhesion, and thrombus deposit formation and adhesion. These were then compared to uncoated HFM bundles and other commercially available biocompatible coatings on HFM. Table 2 provides details of the different coatings.

[0077] Table 2

[0078]

[0079] Materials and methods

[0080] HFM with coating of the present invention

[0081] The efficacy of HFM with the QUAT coating of the present invention and the PVP-QUAT coating was compared to uncoated HFM and HFM coated with other commercially available coatings. QUAT and PVP-QUAT coated HFMs were prepared using the method described above. Before the PVP-QUAT and QUAT coating processes, the HFM fibers were mechanically blocked at both ends to prevent blood from entering through the lumen of the HFM.

[0082] Commercial Coated and Uncoated Hol...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

Hemo-compatible, anti- and non-thrombogenic, heparin-based bioactive coat a surface to be contacted with blood, such as a surface of an oxygenator device (e.g., a Hollow Fiber Membrane (HFM) surface) or an artificial lung, which coatings include a quaternary ammonium salt and heparin complex (QUAT). The surface is treated with polyvinylpyrrolidone (PVP), followed by a coating layer of said quaternary ammonium salts and heparin complex (QUAT) to form a PVP-QUAT coating. According to other example embodiments, anionic functional groups are created on the one or more surfaces of the HFM by modifying the surf ace of the HFM using ionic complexes dissolved in a solvent mixture that includes major quantity of alcohol along with a minor quantity of organic dissolving agents. Also provided are methods of making the provided coatings, methods of coating a surface, devices that have been coated, and kits that include such coatings.

Description

[0001] related application [0002] This application is a PCT application claiming priority to US Provisional Application No. 61 / 749,495, filed January 7, 2013, the entire contents of which are hereby incorporated by reference. [0003] Statement of Federally Funded Research [0004] This invention was developed with government support under Grant Numbers R01HL082631 and R42HL084807 from the National Institutes of Health. The government has certain rights in this invention. technical field [0005] The present invention generally relates to biocompatible coating compositions. More specifically, the present invention relates to hemocompatible, anticoagulant and noncoagulant, heparin-based bioactive coatings for permeable membrane surfaces. Background of the invention [0006] Lung disease may become the third leading cause of death in the United States after cardiovascular disease and cancer. (Lung disease data 2008. American Lung Association. http: / / www.lungusa.org / abou...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/14A61L33/10
CPCA61L33/0011A61L33/0023A61L33/0029C08L39/06A61L33/0076A61L33/04A61L33/064A61L2300/208A61L2300/236A61L2300/42A61L2300/608A61L2420/02A61L2420/06A61L2420/08
Inventor 纳拉亚纳·加里梅拉忠俊·吴巴特利·格里菲思
Owner UNIV OF MARYLAND BALTIMORE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap